and one granulocytic (CD14−HLA-DR−Lin−) based on the expression of CD15 and CD14 markers in the immature myeloid cell population (CD33+CD11b+HLA-DR−Lin−) in the peripheral blood of chemotherapy-naive NSCLC patients (Table 2(b)). This evidence concerns the gene CD33 and non-small cell lung carcinoma.